Foghorn therapeutics provides first quarter 2025 financial and corporate update

Fhd-909 (ly4050784) advancing in phase 1 dose escalation trial in smarca4 (brg1) mutated cancers, with non-small cell lung cancer (nsclc) as the primary target population data presented at aacr show synergistic activity with fhd-909 in combination with pembrolizumab and kras inhibitors and support clinical exploration selective cbp degrader on track for ind-enabling studies, targeting ind in 2026 continued progress on selective ep300 degrader and selective arid1b degrader with program updates expected in h2 2025 strong balance sheet with cash, cash equivalents, and marketable securities of  $220.6 million as of march 31, 2025 , provides cash runway into 2027 cambridge, mass., may 14, 2025 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the company's 10-q filing for the quarter ended march 31, 2025.
FHTX Ratings Summary
FHTX Quant Ranking